Published in:
01-07-2017 | Epidemiology
Role of taxanes in chemotherapy-related cognitive impairment: A prospective longitudinal study
Authors:
Noemí Cerulla, Àngels Arcusa, José-Blas Navarro, Maite Garolera, Cristina Enero, Glòria Chico, Luís Fernández-Morales
Published in:
Breast Cancer Research and Treatment
|
Issue 1/2017
Login to get access
Abstract
Purpose
The aim of this study is to elucidate the role of taxanes on cognition when they are administered as a part of the treatment with a fluorouracil, epirubicin and cyclophosphamide (FEC) regimen for breast cancer (BC).
Methods
Two groups of women (n = 51) with a novel diagnostic of BC that were treated with a combination of FEC alone (6 cycles of FEC) or with taxanes (4 cycles of FEC plus 8 cycles of taxanes) were compared at three moments: before chemotherapy, after its completion (short-term evaluation) and at a mean of 74.5 weeks from baseline as a long-term evaluation.
Results
Both groups showed worsening in tests of attention and executive functions on the short-term assessment, with the group treated with taxanes showing more number of affected cognitive measures at this time point, including verbal learning and speed measures. At the long-term evaluation, cognitive dysfunction was still found in attention and executive functions in both groups.
Conclusion
Our results suggest that chemotherapy for BC with a FEC regimen can have a negative effect on cognition. Acute deficits seem to be larger when taxanes are added, but treatment seems to affect cognition also at long term.